Royalty Pharma plc Financing Receivable, Allowance for Credit Loss, Writeoff
Royalty Pharma plc (RPRX) reported Financing Receivable, Allowance for Credit Loss, Writeoff of $254.48 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Financial Statements › Notes
us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs · last filed 2025-02-12
- Royalty Pharma plc financing receivable, allowance for credit loss, writeoff for the quarter ending 2023-09-30 was $21.05M.
- Royalty Pharma plc financing receivable, allowance for credit loss, writeoff for the quarter ending 2023-06-30 was $16.13M.
- Royalty Pharma plc financing receivable, allowance for credit loss, writeoff for the quarter ending 2023-03-31 was $217.31M.
- Royalty Pharma plc financing receivable, allowance for credit loss, writeoff for the quarter ending 2022-12-31 was -$4.04M.
- Royalty Pharma plc financing receivable, allowance for credit loss, writeoff for fiscal 2022 was $1.58M.
- Royalty Pharma plc financing receivable, allowance for credit loss, writeoff for fiscal 2020 was $25.17M.
| Period end | Financing Receivable, Allowance for Credit Loss, Writeoff 3 month | Financing Receivable, Allowance for Credit Loss, Writeoff 6 month | Financing Receivable, Allowance for Credit Loss, Writeoff 9 month | Financing Receivable, Allowance for Credit Loss, Writeoff 12 month |
|---|---|---|---|---|
| 2023-09-30 | $21.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $37.17M derived: sum of 2 quarters · filed 2023-11-08 | $254.48M 10-Q · filed 2023-11-08 | $250.44M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $16.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $233.43M 10-Q · filed 2023-08-08 | $229.39M derived: sum of 3 quarters · filed 2025-02-12 | |
| 2023-03-31 | $217.31M 10-Q · filed 2023-05-09 | $213.26M derived: sum of 2 quarters · filed 2025-02-12 | ||
| 2022-12-31 | -$4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $1.58M 10-K · filed 2025-02-12 | ||
| 2022-09-30 | $5.63M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | -$469.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$237.81M derived: sum of 2 quarters · filed 2023-02-15 | $25.17M 10-K · filed 2023-02-15 | |
| 2020-09-30 | $231.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $494.26M 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $262.98M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |